Sildenafil, tadalafil i wardenafil – preferencje pacjentów, objawy uboczne, sposób działania. Czy naprawdę trudny wybór? Komentarz
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2009
##plugins.themes.bootstrap3.article.main##
Abstrakt
Brak
##plugins.themes.bootstrap3.article.details##
Jak cytować
Radziszewski, P. (2009). Sildenafil, tadalafil i wardenafil – preferencje pacjentów, objawy uboczne, sposób działania. Czy naprawdę trudny wybór?. Medycyna Faktów , 2(4(5), 22-27. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2628
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Hatzimouratidis K., Hatzichristou D.G.: A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs 2005; 65: 1621-1650.
2. Wespes E., Amar E., Hatzichristou D. et al.: EAU Guidelines on erectile dysfunction: an update. Eur. Urol. 2006; 49: 806-815.
3. Wright P.J.: Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int. J. Clin. Pract. 2006; 60: 967-975.
4. Mulhall J.P., Montorsi F.: Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. Eur. Urol. 2006; 49: 30-37.
5. Mirone V., Fusco F., Rossi A., Sicuteri R., Montorsi F.: Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies. BJU Int. 2009; 103: 1212-1217.
6. Supuran C.T., Mastrolorenzo A., Barbaro G., Scozzafava A.: Phosphodiesterase 5 inhibitors-drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. Curr. Pharm. Des. 2006; 12: 3459-3465.
7. Kell P.D., Hvidsten K., Morant S.V. et al.: Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK. BJU Int. 2007; 99: 860-863.
8. Freitas V.M., Menezes F.G., Antonialli M.M., Nascimento J.W.: Use of phosphodiesterase-5 inhibitors by college students. Rev. Saude. Publica 2008; 42: 965-967.
9. Doggrell S.: Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction? Int. J. Impot. Res. 2007; 19: 281-295.
10. Doggrell S.A.: Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Expert Opin. Pharmacother. 2005; 6: 75-84.
11. Stroberg P., Murphy A., Costigan T.: Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin. Ther. 2003; 25: 2724-2737.
12. Mulhall J.P., McLaughlin T.P. et al.: Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. J. Sex. Med. 2005; 2: 848-855.
13. Ljunggren C., Hedelin H., Salomonsson K., Stroberg P.: Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. J. Sex. Med. 2008; 5: 469-475.
14. Tolra J.R., Campana J.M., Ciutat L.F., Miranda E.F.: Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J. Sex. Med. 2006; 3: 901-909.
15. Taylor J., Baldo O.B., Storey A. et al.: Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. BJU Int. 2009; 103: 1392-1395.
2. Wespes E., Amar E., Hatzichristou D. et al.: EAU Guidelines on erectile dysfunction: an update. Eur. Urol. 2006; 49: 806-815.
3. Wright P.J.: Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int. J. Clin. Pract. 2006; 60: 967-975.
4. Mulhall J.P., Montorsi F.: Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. Eur. Urol. 2006; 49: 30-37.
5. Mirone V., Fusco F., Rossi A., Sicuteri R., Montorsi F.: Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies. BJU Int. 2009; 103: 1212-1217.
6. Supuran C.T., Mastrolorenzo A., Barbaro G., Scozzafava A.: Phosphodiesterase 5 inhibitors-drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. Curr. Pharm. Des. 2006; 12: 3459-3465.
7. Kell P.D., Hvidsten K., Morant S.V. et al.: Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK. BJU Int. 2007; 99: 860-863.
8. Freitas V.M., Menezes F.G., Antonialli M.M., Nascimento J.W.: Use of phosphodiesterase-5 inhibitors by college students. Rev. Saude. Publica 2008; 42: 965-967.
9. Doggrell S.: Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction? Int. J. Impot. Res. 2007; 19: 281-295.
10. Doggrell S.A.: Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Expert Opin. Pharmacother. 2005; 6: 75-84.
11. Stroberg P., Murphy A., Costigan T.: Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin. Ther. 2003; 25: 2724-2737.
12. Mulhall J.P., McLaughlin T.P. et al.: Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. J. Sex. Med. 2005; 2: 848-855.
13. Ljunggren C., Hedelin H., Salomonsson K., Stroberg P.: Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. J. Sex. Med. 2008; 5: 469-475.
14. Tolra J.R., Campana J.M., Ciutat L.F., Miranda E.F.: Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J. Sex. Med. 2006; 3: 901-909.
15. Taylor J., Baldo O.B., Storey A. et al.: Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. BJU Int. 2009; 103: 1392-1395.